Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Ann Pharmacother. 2015 Aug;49(8):907-37. doi: 10.1177/1060028015586218. Epub 2015 May 19.
Ann Pharmacother. 2015.
PMID: 25991832
Review.
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
Horvat TZ, Seddon AN, Ogunniyi A, King AC, Buie LW, Daley RJ.
Horvat TZ, et al.
Ann Pharmacother. 2018 Mar;52(3):268-276. doi: 10.1177/1060028017736539. Epub 2017 Oct 12.
Ann Pharmacother. 2018.
PMID: 29025266
Review.
Item in Clipboard
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.
Horvat TZ, et al.
J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.
J Clin Oncol. 2015.
PMID: 26282644
Free PMC article.
Item in Clipboard
Reply to A. Indini et al.
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.
Horvat TZ, et al.
J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19.
J Clin Oncol. 2016.
PMID: 26786917
No abstract available.
Item in Clipboard
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ.
Buie LW, et al. Among authors: horvat tz.
Ann Pharmacother. 2015 Sep;49(9):1057-67. doi: 10.1177/1060028015588555. Epub 2015 Jun 3.
Ann Pharmacother. 2015.
PMID: 26041811
Review.
Item in Clipboard
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA.
King AC, et al. Among authors: horvat tz.
Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.
Ann Pharmacother. 2017.
PMID: 28056525
Review.
Item in Clipboard
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ, Pecoraro JJ, Daley RJ, Buie LW, King AC, Rampal RK, Tallman MS, Park JH, Douer D.
Horvat TZ, et al.
Leuk Res. 2016 Nov;50:17-20. doi: 10.1016/j.leukres.2016.08.014. Epub 2016 Aug 26.
Leuk Res. 2016.
PMID: 27631159
Free PMC article.
Item in Clipboard
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD.
Stahl M, et al. Among authors: horvat tz.
Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734.
Blood Adv. 2021.
PMID: 33687434
Free PMC article.
Item in Clipboard
Cite
Cite